Inhalation Sciences signs R&D order worth 257,000 SEK with major generic pharma company

Inhalation Sciences AB (ISAB) has signed a new R&D contract worth 257,000 SEK (23,200 Euros) for Inhalation Research Services (IRS) work for a returning, long-standing customer – a major branded generic pharma company.  

A long-standing customer of ISAB’s research services and instruments is outsourcing research and development work worth 257,000 SEK to ISAB during a peak in their development activities.

The work will be carried out using ISAB’s flexible, multi-modular PreciseInhale aerosol generation system that enables precision dosing of a range of in vitro and in vivo exposure modules.

ISAB CEO Manoush Masarrat: “We are happy to continue work with this valued customer who have such great confidence in the unique benefits and flexibility that PreciseInhale bring to their project.”